Matches in Nanopublications for { <http://www.w3.org/2000/01/rdf-schema#SENTENCE> ?p ?o ?g. }
- SENTENCE label "Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction." provenance.
- SENTENCE label "Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction." provenance.
- SENTENCE label "Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction." provenance.
- SENTENCE label "Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction." provenance.
- SENTENCE label "Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction." provenance.
- SENTENCE label "Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction." provenance.
- SENTENCE label "Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction." provenance.
- SENTENCE label "Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction." provenance.
- SENTENCE label "Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction." provenance.
- SENTENCE label "Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction." provenance.
- SENTENCE label "Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction." provenance.
- SENTENCE label "Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction." provenance.
- SENTENCE label "Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction." provenance.
- SENTENCE label "Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction." provenance.
- SENTENCE label "Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction." provenance.
- SENTENCE label "Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction." provenance.
- SENTENCE label "Treatment with the recombinant interleukin-1 (IL)-1) receptor antagonist anakinra and dexamethasone resulted in rapid clinical improvement, reduction in serum inflammatory markers and a marked recovery in CMR-based markers of inflammation and contractile dysfunction." provenance.
- SENTENCE label "Only dexamethasone has been shown to reduce mortality in severe cases, further supporting a role for inflammation in disease severity." provenance.
- SENTENCE label "Only dexamethasone has been shown to reduce mortality in severe cases, further supporting a role for inflammation in disease severity." provenance.
- SENTENCE label "Only dexamethasone has been shown to reduce mortality in severe cases, further supporting a role for inflammation in disease severity." provenance.
- SENTENCE label "Only dexamethasone has been shown to reduce mortality in severe cases, further supporting a role for inflammation in disease severity." provenance.
- SENTENCE label "Only dexamethasone has been shown to reduce mortality in severe cases, further supporting a role for inflammation in disease severity." provenance.
- SENTENCE label "Only dexamethasone has been shown to reduce mortality in severe cases, further supporting a role for inflammation in disease severity." provenance.
- SENTENCE label "Only dexamethasone has been shown to reduce mortality in severe cases, further supporting a role for inflammation in disease severity." provenance.
- SENTENCE label "Only dexamethasone has been shown to reduce mortality in severe cases, further supporting a role for inflammation in disease severity." provenance.
- SENTENCE label "Only dexamethasone has been shown to reduce mortality in severe cases, further supporting a role for inflammation in disease severity." provenance.
- SENTENCE label "Only dexamethasone has been shown to reduce mortality in severe cases, further supporting a role for inflammation in disease severity." provenance.
- SENTENCE label "we recommend using oral or intravenous low-dose dexamethasone in adults with COVID-19 disease who require oxygen or mechanical ventilation." provenance.
- SENTENCE label "we recommend using oral or intravenous low-dose dexamethasone in adults with COVID-19 disease who require oxygen or mechanical ventilation." provenance.
- SENTENCE label "we recommend using oral or intravenous low-dose dexamethasone in adults with COVID-19 disease who require oxygen or mechanical ventilation." provenance.
- SENTENCE label "we recommend using oral or intravenous low-dose dexamethasone in adults with COVID-19 disease who require oxygen or mechanical ventilation." provenance.
- SENTENCE label "we recommend using oral or intravenous low-dose dexamethasone in adults with COVID-19 disease who require oxygen or mechanical ventilation." provenance.
- SENTENCE label "we recommend using oral or intravenous low-dose dexamethasone in adults with COVID-19 disease who require oxygen or mechanical ventilation." provenance.
- SENTENCE label "we recommend using oral or intravenous low-dose dexamethasone in adults with COVID-19 disease who require oxygen or mechanical ventilation." provenance.
- SENTENCE label "we recommend using oral or intravenous low-dose dexamethasone in adults with COVID-19 disease who require oxygen or mechanical ventilation." provenance.
- SENTENCE label "we recommend using oral or intravenous low-dose dexamethasone in adults with COVID-19 disease who require oxygen or mechanical ventilation." provenance.
- SENTENCE label "we recommend using oral or intravenous low-dose dexamethasone in adults with COVID-19 disease who require oxygen or mechanical ventilation." provenance.
- SENTENCE label "we recommend using oral or intravenous low-dose dexamethasone in adults with COVID-19 disease who require oxygen or mechanical ventilation." provenance.
- SENTENCE label "we recommend using oral or intravenous low-dose dexamethasone in adults with COVID-19 disease who require oxygen or mechanical ventilation." provenance.
- SENTENCE label "we recommend using oral or intravenous low-dose dexamethasone in adults with COVID-19 disease who require oxygen or mechanical ventilation." provenance.
- SENTENCE label "we recommend using oral or intravenous low-dose dexamethasone in adults with COVID-19 disease who require oxygen or mechanical ventilation." provenance.
- SENTENCE label "we recommend using oral or intravenous low-dose dexamethasone in adults with COVID-19 disease who require oxygen or mechanical ventilation." provenance.
- SENTENCE label "we recommend using oral or intravenous low-dose dexamethasone in adults with COVID-19 disease who require oxygen or mechanical ventilation." provenance.
- SENTENCE label "we recommend using oral or intravenous low-dose dexamethasone in adults with COVID-19 disease who require oxygen or mechanical ventilation." provenance.
- SENTENCE label "we recommend using oral or intravenous low-dose dexamethasone in adults with COVID-19 disease who require oxygen or mechanical ventilation." provenance.
- SENTENCE label "we recommend using oral or intravenous low-dose dexamethasone in adults with COVID-19 disease who require oxygen or mechanical ventilation." provenance.
- SENTENCE label "we recommend using oral or intravenous low-dose dexamethasone in adults with COVID-19 disease who require oxygen or mechanical ventilation." provenance.
- SENTENCE label "Indeed, dexamethasone, a widely available and inexpensive corticosteroid with anti-inflammatory effects, has shown a great promise in reducing mortality rates in COVID-19 patients." provenance.
- SENTENCE label "Indeed, dexamethasone, a widely available and inexpensive corticosteroid with anti-inflammatory effects, has shown a great promise in reducing mortality rates in COVID-19 patients." provenance.
- SENTENCE label "Indeed, dexamethasone, a widely available and inexpensive corticosteroid with anti-inflammatory effects, has shown a great promise in reducing mortality rates in COVID-19 patients." provenance.
- SENTENCE label "Indeed, dexamethasone, a widely available and inexpensive corticosteroid with anti-inflammatory effects, has shown a great promise in reducing mortality rates in COVID-19 patients." provenance.
- SENTENCE label "Indeed, dexamethasone, a widely available and inexpensive corticosteroid with anti-inflammatory effects, has shown a great promise in reducing mortality rates in COVID-19 patients." provenance.
- SENTENCE label "Indeed, dexamethasone, a widely available and inexpensive corticosteroid with anti-inflammatory effects, has shown a great promise in reducing mortality rates in COVID-19 patients." provenance.
- SENTENCE label "Indeed, dexamethasone, a widely available and inexpensive corticosteroid with anti-inflammatory effects, has shown a great promise in reducing mortality rates in COVID-19 patients." provenance.
- SENTENCE label "Indeed, dexamethasone, a widely available and inexpensive corticosteroid with anti-inflammatory effects, has shown a great promise in reducing mortality rates in COVID-19 patients." provenance.
- SENTENCE label "Indeed, dexamethasone, a widely available and inexpensive corticosteroid with anti-inflammatory effects, has shown a great promise in reducing mortality rates in COVID-19 patients." provenance.
- SENTENCE label "Indeed, dexamethasone, a widely available and inexpensive corticosteroid with anti-inflammatory effects, has shown a great promise in reducing mortality rates in COVID-19 patients." provenance.
- SENTENCE label "Indeed, dexamethasone, a widely available and inexpensive corticosteroid with anti-inflammatory effects, has shown a great promise in reducing mortality rates in COVID-19 patients." provenance.
- SENTENCE label "Indeed, dexamethasone, a widely available and inexpensive corticosteroid with anti-inflammatory effects, has shown a great promise in reducing mortality rates in COVID-19 patients." provenance.
- SENTENCE label "Indeed, dexamethasone, a widely available and inexpensive corticosteroid with anti-inflammatory effects, has shown a great promise in reducing mortality rates in COVID-19 patients." provenance.
- SENTENCE label "Indeed, dexamethasone, a widely available and inexpensive corticosteroid with anti-inflammatory effects, has shown a great promise in reducing mortality rates in COVID-19 patients." provenance.
- SENTENCE label "Indeed, dexamethasone, a widely available and inexpensive corticosteroid with anti-inflammatory effects, has shown a great promise in reducing mortality rates in COVID-19 patients." provenance.
- SENTENCE label "Indeed, dexamethasone, a widely available and inexpensive corticosteroid with anti-inflammatory effects, has shown a great promise in reducing mortality rates in COVID-19 patients." provenance.
- SENTENCE label "Indeed, dexamethasone, a widely available and inexpensive corticosteroid with anti-inflammatory effects, has shown a great promise in reducing mortality rates in COVID-19 patients." provenance.
- SENTENCE label "Indeed, dexamethasone, a widely available and inexpensive corticosteroid with anti-inflammatory effects, has shown a great promise in reducing mortality rates in COVID-19 patients." provenance.
- SENTENCE label "Indeed, dexamethasone, a widely available and inexpensive corticosteroid with anti-inflammatory effects, has shown a great promise in reducing mortality rates in COVID-19 patients." provenance.
- SENTENCE label "Indeed, dexamethasone, a widely available and inexpensive corticosteroid with anti-inflammatory effects, has shown a great promise in reducing mortality rates in COVID-19 patients." provenance.
- SENTENCE label "Indeed, dexamethasone, a widely available and inexpensive corticosteroid with anti-inflammatory effects, has shown a great promise in reducing mortality rates in COVID-19 patients." provenance.
- SENTENCE label "Indeed, dexamethasone, a widely available and inexpensive corticosteroid with anti-inflammatory effects, has shown a great promise in reducing mortality rates in COVID-19 patients." provenance.
- SENTENCE label "Indeed, dexamethasone, a widely available and inexpensive corticosteroid with anti-inflammatory effects, has shown a great promise in reducing mortality rates in COVID-19 patients." provenance.
- SENTENCE label "Indeed, dexamethasone, a widely available and inexpensive corticosteroid with anti-inflammatory effects, has shown a great promise in reducing mortality rates in COVID-19 patients." provenance.
- SENTENCE label "In vitro dexamethasone inhibited tissue inflammation via macrophages MerTK function." provenance.
- SENTENCE label "In vitro dexamethasone inhibited tissue inflammation via macrophages MerTK function." provenance.
- SENTENCE label "In vitro dexamethasone inhibited tissue inflammation via macrophages MerTK function." provenance.
- SENTENCE label "In vitro dexamethasone inhibited tissue inflammation via macrophages MerTK function." provenance.
- SENTENCE label "Reducing dexamethasone antiemetic prophylaxis during the COVID-19 pandemic: recommendations from Ontario, Canada" provenance.
- SENTENCE label "Reducing dexamethasone antiemetic prophylaxis during the COVID-19 pandemic: recommendations from Ontario, Canada" provenance.
- SENTENCE label "Reducing dexamethasone antiemetic prophylaxis during the COVID-19 pandemic: recommendations from Ontario, Canada" provenance.
- SENTENCE label "Reducing dexamethasone antiemetic prophylaxis during the COVID-19 pandemic: recommendations from Ontario, Canada" provenance.
- SENTENCE label "Reducing dexamethasone antiemetic prophylaxis during the COVID-19 pandemic: recommendations from Ontario, Canada" provenance.
- SENTENCE label "Reducing dexamethasone antiemetic prophylaxis during the COVID-19 pandemic: recommendations from Ontario, Canada" provenance.
- SENTENCE label "Reducing dexamethasone antiemetic prophylaxis during the COVID-19 pandemic: recommendations from Ontario, Canada" provenance.
- SENTENCE label "Reducing dexamethasone antiemetic prophylaxis during the COVID-19 pandemic: recommendations from Ontario, Canada" provenance.
- SENTENCE label "Reducing dexamethasone antiemetic prophylaxis during the COVID-19 pandemic: recommendations from Ontario, Canada" provenance.
- SENTENCE label "Reducing dexamethasone antiemetic prophylaxis during the COVID-19 pandemic: recommendations from Ontario, Canada" provenance.
- SENTENCE label "Reducing dexamethasone antiemetic prophylaxis during the COVID-19 pandemic: recommendations from Ontario, Canada" provenance.
- SENTENCE label "Reducing dexamethasone antiemetic prophylaxis during the COVID-19 pandemic: recommendations from Ontario, Canada" provenance.
- SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
- SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
- SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
- SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
- SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
- SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
- SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
- SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
- SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
- SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
- SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
- SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
- SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.